Literature DB >> 17880855

Antipsychotic treatment of schizophrenia: two steps forward, one step back.

Rajiv Tandon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17880855     DOI： 10.1007/s11920-007-0029-3

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


× No keyword cloud information.
  13 in total

Review 1.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.

Authors:  Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F Gattaz; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2005       Impact factor: 4.132

Review 2.  Strategies for maximizing clinical effectiveness in the treatment of schizophrenia.

Authors:  Rajiv Tandon; Steven D Targum; Henry A Nasrallah; Ruth Ross
Journal:  J Psychiatr Pract       Date:  2006-11       Impact factor: 1.325

Review 3.  Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.

Authors:  Stephan Heres; John Davis; Katja Maino; Elisabeth Jetzinger; Werner Kissling; Stefan Leucht
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

4.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Authors:  Peter B Jones; Thomas R E Barnes; Linda Davies; Graham Dunn; Helen Lloyd; Karen P Hayhurst; Robin M Murray; Alison Markwick; Shôn W Lewis
Journal:  Arch Gen Psychiatry       Date:  2006-10

5.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 7.  Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria.

Authors:  Jes Gerlach
Journal:  Ann Clin Psychiatry       Date:  2002-03       Impact factor: 1.567

8.  Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

Authors:  Marvin S Swartz; Diana O Perkins; T Scott Stroup; Sonia M Davis; George Capuano; Robert A Rosenheck; Fred Reimherr; Mark F McGee; Richard S E Keefe; Joseph P McEvoy; John K Hsiao; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2007-03       Impact factor: 18.112

Review 9.  New atypical antipsychotic medications.

Authors:  M D Jibson; R Tandon
Journal:  J Psychiatr Res       Date:  1998 May-Aug       Impact factor: 4.791

Review 10.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.

Authors:  Alexander L Miller; Catherine S Hall; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Larry Ereshefsky; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; A John Rush; Sy A Saeed; Nina R Schooler; Steven P Shon; Scott Stroup; Bernardo Tarin-Godoy
Journal:  J Clin Psychiatry       Date:  2004-04       Impact factor: 4.384
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.